Coeptis Therapeutics' SEC-Approved S-4 Clears Path For Z Squared Merger, Stockholder Vote Set For January 30

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, , announced today that its registration statement on Form S-4 (File No. 333-288329) (as amended, the "Registration Statement"), relating to the previously announced merger transaction (the "Transaction") with Z Squared Inc. ("ZSQ"), has been declared effective by the U.S. Securities and Exchange Commission ("SEC") and that it will commence mailing the definitive proxy statement/prospectus relating to the Annual/Special Meeting (the "Stockholder Meeting") of the Company's stockholders to be held on January 30, 2026, in connection with the Transaction. The proxy statement/prospectus is being mailed to the Company's stockholders of record as of the close of business on January 2, 2026 (the "Record Date"). Notice of the Stockholder Meeting will be mailed on or about January 7, 2026 to stockholders of record as of the Record Date.

While the combined company has submitted an application to list the combined company's common stock on The Nasdaq Stock Market LLC, approval has not yet been obtained and there can be no assurance that such listing application will be approved or that the combined company will meet the applicable listing standards. If the combined company is unable to obtain listing on a national securities exchange, the combined company's securities will continue to trade on the OTC Markets following the Transaction.

About Coeptis.